 Was responsible for strategic planning and business plan, seeking new distributors, analysis of contracts, goals, and results, overseeing a sales portfolio of ~US$30M/year. Created a workflow and management plan together with the U.S. headquarters, suggesting and creating implementation solutions for the Latin American market. Preparation of P&L and forecast together with the U.S. headquarters.  Led IVD Diagnostics indirect sales teams across Latin America. Managed… Show more  Was responsible for strategic planning and business plan, seeking new distributors, analysis of contracts, goals, and results, overseeing a sales portfolio of ~US$30M/year. Created a workflow and management plan together with the U.S. headquarters, suggesting and creating implementation solutions for the Latin American market. Preparation of P&L and forecast together with the U.S. headquarters.  Led IVD Diagnostics indirect sales teams across Latin America. Managed distributors’ actions in the areas of RAQA (regulatory and quality), Services and Technical Support, Supply Chain, and Finance.  Promoted market access for the implementation of Molecular Biology & 3D Mammography techniques, interfacing with Supplementary Healthcare, CONITEC (National Committee for Health Technology Incorporation) – SUS. Conducted training and planning with distributors on Breast and Gynecological Oncology technologies, inventory levels, technical communications, and KPIs. Show less

 Strategic development involving portfolio products in Brazil and Latin America. Access to public women's health system providing molecular techniques for screening cervical cancer (HPV) and tuberculosis (TB); access to the supplementary healthcare system (health insurance, medical cooperatives, and hospitals). Conducted planning for market entry of Latent Tuberculosis technology QuantiFeron® in the public and supplementary healthcare system (National Regulatory Agency for Private… Show more  Strategic development involving portfolio products in Brazil and Latin America. Access to public women's health system providing molecular techniques for screening cervical cancer (HPV) and tuberculosis (TB); access to the supplementary healthcare system (health insurance, medical cooperatives, and hospitals). Conducted planning for market entry of Latent Tuberculosis technology QuantiFeron® in the public and supplementary healthcare system (National Regulatory Agency for Private Health Insurance and Plans, ANS).  Relationship with healthcare associations and committees, as well as opinion leaders, to work on public health projects at municipal, state, and federal levels, with participation in national and international events. Show less

• Managed and implemented strategies for product sale in Molecular Biology with a focus on public and private markets, including Diagnostics, Life Sciences, Applied Tests, Forensic, Food, and Veterinary Tests with an average growth of 70%/year, reporting directly to the VP Brazil & LATAM.• Led commercial actions, with a sales team comprised of 8 direct (sales representatives) and 6 indirect reports (distributors).• Was responsible for a nationwide Clinical Sales project (10 clinical… Show more • Managed and implemented strategies for product sale in Molecular Biology with a focus on public and private markets, including Diagnostics, Life Sciences, Applied Tests, Forensic, Food, and Veterinary Tests with an average growth of 70%/year, reporting directly to the VP Brazil & LATAM.• Led commercial actions, with a sales team comprised of 8 direct (sales representatives) and 6 indirect reports (distributors).• Was responsible for a nationwide Clinical Sales project (10 clinical sales) aimed at promoting the prescription of molecular tests (HPV tests).• Goal development and control; market analysis for launching and introducing new technologies and a pilot study for rapid testing in remote areas.• Experienced relationship with Ministries, NGOs, and International Research and Oncology Centers, as well as pharmaceutical companies including Amgen and AstraZeneca, involving exams such as EGFR, KRAS, NRAS, and BRAF in partnership with Qiagen.• Implementation of SFDC, a sales force system and process, ensuring greater visibility and control of KPIs. Show less

 Was responsible for the company's main accounts, representing 55% of revenue, overseeing the entire operational and technical customer support process. Commercial management involving the approval of Life Science products for Embrapas, Blood Banks, Applied and private sector providers, Albert Einstein Hospital, and Santa Casa system (LS and Dx).

 Was responsible for the sale of products in the lines of autoimmunity, biochemistry, and immunology in the São Paulo state (inland and capital city).  Managed and expanded private and public accounts in São Paulo.

 Was responsible for sales and technical/commercial support for key accounts.  Implementation of the innovative DNA-Citoliq liquid-based cytology technology, enabling the opening of 40 new accounts for Hybrid Capture and achieving sales growth.